CLINICAL AND THERAPEUTIC ASSESSMENT OF TREATMENT-RESISTANT DEPRESSION AFTER GENE VARIATION TESTING
Guardat en:
| Publicat a: | Journal of Psychological and Educational Research vol. 33, no. 1 (May 2025), p. 222 |
|---|---|
| Autor principal: | |
| Altres autors: | , , , , , , |
| Publicat: |
University of Oradea, Faculty of Social and Humanistic Sciences
|
| Matèries: | |
| Accés en línia: | Citation/Abstract Full Text Full Text - PDF |
| Etiquetes: |
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|
MARC
| LEADER | 00000nab a2200000uu 4500 | ||
|---|---|---|---|
| 001 | 3219367614 | ||
| 003 | UK-CbPIL | ||
| 022 | |a 2247-1537 | ||
| 022 | |a 1583-2910 | ||
| 035 | |a 3219367614 | ||
| 045 | 2 | |b d20250501 |b d20250531 | |
| 084 | |a 155331 |2 nlm | ||
| 100 | 1 | |a Platona, Rita Ioana |u University of Oradea, Romania | |
| 245 | 1 | |a CLINICAL AND THERAPEUTIC ASSESSMENT OF TREATMENT-RESISTANT DEPRESSION AFTER GENE VARIATION TESTING | |
| 260 | |b University of Oradea, Faculty of Social and Humanistic Sciences |c May 2025 | ||
| 513 | |a Journal Article | ||
| 520 | 3 | |a The mail objective of this study is to identificate the variations in 5 genes, of which 3 are pharmacokinetic (CYP2B6, CYP2C19, CYP2D6) and 2 pharmacodynamic (SLC6A4, HTRA2), used to optimize therapy in patients with treatment-resistant depression (TRD) using pharmacogenomic testing (PGx) and monitoring clinical evolution by using the psychometric scales HAM-D and CGI-S in the initial stage (T1) and later HAM-D at 1 month (T2), 3 months (T3), 6 months (T4) and 12 months (T5). Depressive disorder is a public health problem because this pathology has a high tendency of recurrence, is the second cause of disability worldwide and has high costs. The depressive episode causes suffering to both the person and the family and relatives. In this longitudinal prospective study, we included 128 patients from the outpatient clinic of the PsihoNeuroMag Clinic in Oradea, Romania, diagnosed with TRD. The two groups presented during the research, were compared in the pretest stage (T1) as well as in the posttest stage according to the genetic testing using the t-test for independent samples. The onset age of the patients in the pharmacogenomic testing group is younger, but significant differences were indicated in the case of gender, the environment of origin and the number of recorded relapses. CYP2B6 gene analysis indicates relevant data in TRD course change between the HAM-D testing phase (between TI and T5). When CYP2B6 is at a low level, the class of drugs was most frequently changed and neuroleptics or thymostabilizers were associated and thus improvements were obtained between the baseline and the HAM-D evaluation at 12 months. | |
| 610 | 4 | |a European Medicines Agency Food & Drug Administration--FDA | |
| 651 | 4 | |a United States--US | |
| 651 | 4 | |a Romania | |
| 653 | |a Outpatient care facilities | ||
| 653 | |a Antidepressants | ||
| 653 | |a Genomes | ||
| 653 | |a Genes | ||
| 653 | |a Treatment resistance | ||
| 653 | |a Genetic testing | ||
| 653 | |a Patients | ||
| 653 | |a Quality of life | ||
| 653 | |a Pharmacodynamics | ||
| 653 | |a Medical history | ||
| 653 | |a Quantitative psychology | ||
| 653 | |a Public health | ||
| 653 | |a Pharmacokinetics | ||
| 653 | |a Mental depression | ||
| 653 | |a Health problems | ||
| 653 | |a Age of onset | ||
| 653 | |a Disorders | ||
| 653 | |a Refractory depression | ||
| 653 | |a Relapse | ||
| 653 | |a Psychological assessment | ||
| 653 | |a Clinical assessment | ||
| 653 | |a Relatives | ||
| 653 | |a Longitudinal studies | ||
| 653 | |a Pathology | ||
| 653 | |a Prescription drugs | ||
| 653 | |a Depressive personality disorders | ||
| 653 | |a Medical treatment | ||
| 653 | |a Therapy | ||
| 653 | |a Recurrence | ||
| 653 | |a Antipsychotics | ||
| 653 | |a Drugs | ||
| 653 | |a Depression (Psychology) | ||
| 653 | |a Drug Addiction | ||
| 653 | |a Physicians | ||
| 653 | |a World Problems | ||
| 653 | |a Rating Scales | ||
| 653 | |a Sleep | ||
| 653 | |a Genetics | ||
| 653 | |a Measurement Techniques | ||
| 653 | |a Drug Therapy | ||
| 653 | |a Psychometrics | ||
| 653 | |a Data Analysis | ||
| 653 | |a Mental Disorders | ||
| 700 | 1 | |a Buzlea, Călin David |u University of Oradea, Romania | |
| 700 | 1 | |a Vîlceanu, Ioana |u University of Oradea, Romania | |
| 700 | 1 | |a Szilagyi, Gheorghe |u University of Oradea, Romania | |
| 700 | 1 | |a Voiţă-Mekeres, Florica |u University of Oradea, Romania | |
| 700 | 1 | |a Voiţă, Ioan Bogdan | |
| 700 | 1 | |a Osiceanu, Alina | |
| 700 | 1 | |a Bonţea, Mihaela Gabriela | |
| 773 | 0 | |t Journal of Psychological and Educational Research |g vol. 33, no. 1 (May 2025), p. 222 | |
| 786 | 0 | |d ProQuest |t Psychology Collection | |
| 856 | 4 | 1 | |3 Citation/Abstract |u https://www.proquest.com/docview/3219367614/abstract/embedded/L8HZQI7Z43R0LA5T?source=fedsrch |
| 856 | 4 | 0 | |3 Full Text |u https://www.proquest.com/docview/3219367614/fulltext/embedded/L8HZQI7Z43R0LA5T?source=fedsrch |
| 856 | 4 | 0 | |3 Full Text - PDF |u https://www.proquest.com/docview/3219367614/fulltextPDF/embedded/L8HZQI7Z43R0LA5T?source=fedsrch |